Overview
- Product nameAnti-PARP3 antibodySee all PARP3 primary antibodies ...
- DescriptionGoat polyclonal to PARP3
- Tested applicationsIHC-P more details
- Species reactivityReacts with: Human
- Immunogen
Synthetic peptide: YEDYNCTLNQTNIEN, corresponding to internal sequence amino acids 63-77 of Human PARP3 (NP_001003931.2; NP_001003935.2)
- Positive controlHuman kidney and liver tissue.
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA -
Concentration information loading... - PurityImmunogen affinity purified
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab110154 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| IHC-P | IHC-P: Use a concentration of 3.75 µg/ml. |
Target
- FunctionInvolved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. Negatively influences the G1/S cell cycle progression without interfering with centrosome duplication. Binds DNA. May be involved in the regulation of PRC2 and PRC3 complex-dependent gene silencing.
- Tissue specificityWidely expressed; the highest levels are in the kidney, skeletal muscle, liver, heart and spleen; also detected in pancreas, lung, placenta, brain, leukocytes, colon, small intestine, ovary, testis, prostate and thymus.
- Sequence similaritiesContains 1 PARP alpha-helical domain.
Contains 1 PARP catalytic domain. - DomainAccording to PubMed:10329013, the N-terminal domain (54 amino acids) of isoform 2 is responsible for its centrosomal localization. The C-terminal region contains the catalytic domain.
- Post-translational
modificationsAuto-poly(ADP)-ribosylation. - Cellular localizationNucleus. Cytoplasm > cytoskeleton > centrosome. Cytoplasm > cytoskeleton > centrosome > centriole. Core component of the centrosome. Preferentially localized to the daughter centriole throughout the cell cycle. According to PubMed:16924674, it is almost exclusively localized in the nucleus and appears in numerous small foci and a small number of larger foci whereas a centrosomal location has not been detected.
-
Database links
- Entrez Gene: 10039 Human
- Entrez Gene: 10039 Human
- Omim: 607726 Human
- SwissProt: Q9Y6F1 Human
- SwissProt: Q9Y6F1 Human
- Unigene: 271742 Human
Target information above from: UniProt accession
Q9Y6F1
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- ADP ribosyltransferase (NAD+; poly (ADP ribose) antibodyADPRT-3 antibodyADPRT3 antibody
- ADPRTL2 antibodyADPRTL3 antibodyhPARP 3 antibodyhPARP-3 antibodyhPARP3 antibodyIRT 1 antibodyIRT1 antibodyIRT1 antibodyNAD(+) ADP ribosyltransferase 3 antibodyNAD(+) ADP-ribosyltransferase 3 antibodyNAD+ ADP ribosyltransferase 3 antibodypADPRT 3 antibodypADPRT-3 antibodypADPRT3 antibodyPARP 3 antibodyPARP-3 antibodyPARP3 antibodyPARP3_HUMAN antibodyPoly (ADP ribose) polymerase family, member 3 antibodyPoly (ADP ribose) synthetase 3 antibodyPoly [ADP-ribose] polymerase 3 antibodyPoly[ADP ribose] synthetase 3 antibodyPoly[ADP-ribose] synthase 3 antibody
see all
Anti-PARP3 antibody images
-
Immunohistochemical analysis of Formalin-Fixed, Paraffin-Embedded Human Kidney using ab110154 at 3.75µg/ml.
-
Immunohistochemical analysis of Formalin-Fixed, Paraffin-Embedded Human Liver using ab110154 at 3.75µg/ml
References for Anti-PARP3 antibody (ab110154)
ab110154 has not yet been referenced specifically in any publications.



